title: The additive effects on intraocular pressure of combining nipradilol 0.25% and latanoprost 0.005% ophthalmic solutions: a prospective, randomized, multicenter study.
abstract: OBJECTIVE
  To investigate the effectiveness of combining nipradilol 0.25% and latanoprost 0.005% ophthalmic solutions in improving the intraocular pressures (IOPs) in glaucoma patients.
  
  
  METHODS
  We divided the 53 patients into two groups, those who had been treated with latanoprost and those who had been treated with nipradilol. We administered to the first group one dose of latanoprost daily for 12 weeks and to the second group one dose of nipradilol daily for 12 weeks. Each group then received both solutions for another 12 weeks; the latanoprost group received nipradilol and the nipradilol group received latanoprost. IOPs were measured at each 4-week visit.
  
  
  RESULTS
  In the patients previously treated with latanoprost, the mean IOP was 19.6+/-2.5 mmHg at baseline, and 14.9+/-2.4 mmHg (23.7% reduction) after 12 weeks of latanoprost monotherapy. The addition of nipradilol decreased the IOP to 13.8+/-1.9 mmHg (29.0% reduction). In the group previously treated with nipradilol, the mean IOP was 20.2+/-3.1 mmHg at baseline, and 16.7+/-3.5 mmHg (17.1% reduction) after 12 weeks of nipradilol monotherapy. Addition of latanoprost decreased the IOP to 14.2+/-3.2 mmHg (29.5% reduction).
  
  
  CONCLUSIONS
  Latanoprost and nipradilol are more effective as a combination therapy than each one by itself.
authors.affiliation: Department of Ophthalmology, Jichi Medical University School of Medicine, Tochigi, Japan. ttsuru@jichi.ac.jp.|Tadahiko Tsuru, Department of Ophthalmology, Jichi Medical University School of Medicine, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan. ttsuru@jichi.ac.jp.
authors.forename: Tadahiko
authors.initials: T
authors.lastname: Tsuru
authors.affiliation: Akasaka Kitazawa Eye Clinic, Tokyo, Japan.
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Kitazawa
authors.affiliation: 3 Department of Ophthalmology, Tokyo Medical University, Tokyo, Japan.
authors.forename: Masahiko
authors.initials: M
authors.lastname: Usui
authors.affiliation: Department of Ophthalmology, St. Marianna University School of Medicine, Kanagawa, Japan.
authors.forename: Satoki
authors.initials: S
authors.lastname: Ueno
authors.affiliation: Osaka Medical College, Osaka, Japan.
authors.forename: Ikuo
authors.initials: I
authors.lastname: Azuma
authors.affiliation: Japanese Red Cross Medical Center, Tokyo, Japan.
authors.forename: Kanjiro
authors.initials: K
authors.lastname: Masuda
mesh_terms: D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D000077338:Latanoprost; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions / Q000009:adverse effects / Q000627:therapeutic use; D011412:Propanolamines / Q000009:adverse effects / Q000627:therapeutic use*; D011446:Prospective Studies; D011461:Prostaglandins F, Synthetic / Q000009:adverse effects / Q000627:therapeutic use*; D014065:Tonometry, Ocular; D016896:Treatment Outcome; D014794:Visual Fields / Q000187:drug effects
chemical_list: D000959:Antihypertensive Agents; D009883:Ophthalmic Solutions; D011412:Propanolamines; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost; C036089:nipradilol